Integrated Bioinformatics and Experimental Validation of Shared Genetic Targets in AKI and Ovarian Cancer for reserpine-based Therapeutics

Open Access

Issue		BIO Web Conf. Volume 233, 2026 9^th International Conference on Advances in Biosciences and Biotechnology: Emerging Innovations in Biomedical and Bioengineering Sciences (ICABB 2026)


Article Number		01015
Number of page(s)		12
Section		Biomedical and Health Innovations
DOI		https://doi.org/10.1051/bioconf/202623301015
Published online		23 April 2026

Taylor AH, Ayakannu T. Renal Dysfunction in Gynaecological Cancers. Ann Med Clin Oncol 2024;7:161. https://doi.org/10.29011/2833-3497.000161. [Google Scholar]
Donadio C, Lucchesi A, Ardini M, Cosio S, Gadducci A. Renal impairment in patients with ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2003;106:198–202. https://doi.org/10.1016/S0301-2115(02)00234-8. [Google Scholar]
Xu N, Mu R, Deng S, Han Y, Shi Y, Fu X, et al. Reserpine alleviates cisplatin-induced acute kidney injury via anti-ferroptosis and cGAS/STING pathway. Ren Fail 2024;46. https://doi.org/10.1080/0886022X.2024.2406395. [Google Scholar]
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2012;41:D991–5. https://doi.org/10.1093/nar/gks1193. [Google Scholar]
Chen Q, Mao Y, Cai S, Zhang X, Zeng C, Chen Q, et al. Integrated bioinformatics and molecular docking analysis reveal potential hub genes and targeted therapeutics in sepsis-associated acute lung injury. Front Immunol 2025;16. https://doi.org/10.3389/fimmu.2025.1684774. [Google Scholar]
Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83–96. https://doi.org/10.1038/nrc3430. [Google Scholar]
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in Uveal Melanoma. New England Journal of Medicine 2010;363:2191–9. https://doi.org/10.1056/NEJMoa1000584. [Google Scholar]
Sheldon LA. Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein. Cell Cycle 2017;16:2058–72. https://doi.org/10.1080/15384101.2017.1338221. [Google Scholar]
Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33–45. https://doi.org/10.1038/nrm1004. [Google Scholar]
Araujo JM, Gomez AC, Aguilar A, Salgado R, Balko JM, Bravo L, et al. Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Sci Rep 2018;8:4899. https://doi.org/10.1038/s41598-018-23099-7. [Google Scholar]
Nishitani H, Taraviras S, Lygerou Z, Nishimoto T. The Human Licensing Factor for DNA Replication Cdt1 Accumulates in G1 and Is Destabilized after Initiation of S-phase. Journal of Biological Chemistry 2001;276:44905–11. https://doi.org/10.1074/jbc.M105406200. [Google Scholar]
Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med 2016;22:128–34. https://doi.org/10.1038/nm.4036. [Google Scholar]
Zhou Q, Xiao J, Liu Y. Participation of syntaxin 1A in membrane trafficking involving neurite elongation and membrane expansion. J Neurosci Res 2000;61:321–8. https://doi.org/10.1002/1097-4547(20000801)61:3<321::AID-JNR10>3.0.CO;2-L. [Google Scholar]
Moyer SE, Lewis PW, Botchan MR. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proceedings of the National Academy of Sciences 2006;103:10236–41. https://doi.org/10.1073/pnas.0602400103. [Google Scholar]
Luong TT, Bernstein KA. Role and Regulation of the RECQL4 Family during Genomic Integrity Maintenance. Genes (Basel) 2021;12:1919. https://doi.org/10.3390/genes12121919. [Google Scholar]
Dolphin AC. Calcium channel auxiliary a25 and 0 subunits: trafficking and one step beyond. Nat Rev Neurosci 2012;13:542–55. https://doi.org/10.1038/nrn3311. [Google Scholar]
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720–32. https://doi.org/10.1182/blood-2010-07-273417. [Google Scholar]
Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. Annual Review of Pathology: Mechanisms of Disease 2016;11:617–44. https://doi.org/10.1146/annurev-pathol-012414-040349. [Google Scholar]
Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther 2025;10:106. https://doi.org/10.1038/s41392-025-02142-w. [Google Scholar]
Rao Z-Y, Cai M-Y, Yang G-F, He L-R, Mai S-J, Hua W-F, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-01 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010;31:1576–83. https://doi.org/10.1093/carcin/bgq150. [Google Scholar]
Raguraman S, Almoallim HS, Alahmadi TA, Hussein-Al-Ali SH, Bharathi M, Ramu AK. Reserpine Induces Apoptosis in Drug-Resistant Cancer through Modulating STAT3 and NF-kB Signaling. Indian Journal of Pharmaceutical Education and Research 2024;58:s900–9. https://doi.org/10.5530/ijper.58.3s.91. [Google Scholar]
Sohail A, Shams F, Nawaz A, Ain Q ul, Ijaz B. Antifibrotic potential of reserpine (alkaloid) targeting Keap1/Nrf2; oxidative stress pathway in CCl4-induced liver fibrosis. Chem Biol Interact 2025;407:111384. https://doi.org/10.1016/j.cbi.2025.111384. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.